References
- Mitchell J. D., O'Brien M. R., Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord 2006; 7: 67–71
- Zoccolella S., Beghi E., Palagano G., Fraddosio A., Guerra V., Lepore V., et al. Riluzole and amyotrophic lateral sclerosis survival: a population‐based study in southern Italy. Neurology 2006; 66((Suppl 2))231
- Traynor B. J., Alexander M., Corr B., Frost E., Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis: population‐based study in Ireland 1996–2000. J Neurol 2003; 250: 473–9
- Logroscino G., Traynor B. J., Hardiman O., Chio A., Couratier P., Mitchell J. D., et al. EURALS. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. JNNP. 2006, In press
- O'Toole O., Traynor B. J., Sheehan B. S., Frost E., Corr B., Hardiman O. Epidemiology, survival and clinical features of amyotrophic lateral Ssclerosis in Ireland, JNNP 1995–2004. 2006, Submitted
- Miller R. G., Scholtz D., Moore D. H., Spitalny G. M., Fox C., Katz J., et al. Treatment of patients with ALS in the community: new insights from the web‐based ALS patient care database. Amyotroph Lateral Scler Other Motor Neuron Disord 2006; 7: 56–7
- Concato J., Shah N., Horwitz R. I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New England Journal of Medicine 2000; 342: 1887–92
- Bensimon G., Lacomblez L., Delumeau J. C., Bejuit R., Truffinet P., Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002; 249: 609–15
- Rosenbaum P. R., Rubin D. B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41–55
- de Carvalho M., Costa J., Swash M. Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 202–12